Companies Dominating the Cell Viability Assays Landscape
- Thermo Fisher Scientific Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Agilent Technologies, Inc.
- Bio-Rad Laboratories Inc.
- Merck KGaA
- Becton, Dickinson and Company (BD)
- PerkinElmer Inc.
- Promega Corporation
- Biotium, Inc.
- Creative Bioarray
- Abcam Plc.
Browse Key Market Insights with Data Illustration:
In the News
- The improved applied Biosystems HIV-1 Genotyping Kit was released by Thermo Fisher Scientific, Inc. The new kit complements the previously released Applied Biosystems MagMax Viral/Pathogen Nucleic Acid Isolation Kit for HIV-1 Blood Sports. With the aid of this device, labs may monitor HIV mutations to antiretroviral treatment inhibitors using a cutting-edge method for drug resistance surveillance.
- The BD Rhapsody TCR/BCR Multiomic Assay, a cutting-edge set of reagents that enables researchers to more easily and thoroughly analyze crucial immune system cells, was released by BD (Becton, Dickinson, and Company), a leading global medical technology company. This assay would then be used to advance research on autoimmune disorders, immune oncology, and infectious diseases.